Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Press Releases
Read more
Recent/Upcoming Events
Jun 25, 2024 at 9:10 AM EDT
The 7th Global MASLD Congress

Presentation Title: Role of glucagon-containing dual and triple agonists in the treatment of obesity and MASH

Speaker: Dr. Scott Harris, Chief Medical Officer, Altimmune

Jun 23, 2024 at 1:45 PM EDT
American Diabetes Association’s (ADA) 84th Scientific Sessions

Presentation Title: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity –A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

Speaker: Louis Aronne, M.D., Professor of Metabolic Research and Professor of Clinical Medicine, Weil Cornell Medical School

 

View all

Corporate Governance

Corporate Presentation
 

Investor Contact

Email: ir@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe